Flyer

Translational Biomedicine

  • ISSN: 2172-0479
  • Journal h-index: 18
  • Journal CiteScore: 5.91
  • Journal Impact Factor: 4.11
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • ResearchBible
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Abstract

Accomplish of Cosolvents and Surfactants on the Rate Constant (Log K) of Sparfloxacin

Ruth EG* and Chika MJ

Sparfloxacin, a difluoroquinolone antibacterial agent is clinically used in the treatment of streptococci and community-acquired lower respiratory tract infections. The aim of the present study was to investigate to what extent cosolvents and surfactants could affect sparfloxacin degradation kinetics under acidic condition. The degradation of sparfloxacin in acidic aqueous solution of cosolvents and surfactants at 60 ± 0.2°C was studied. The degradation was determined by UV spectrometry. The degradation was observed to follow apparent first-order rate kinetics and the rate constants for the decomposition were obtained from plots of logarithm percent drug concentration remaining versus time. The reaction was shown to be hydrogen ion catalysed. Significant increase in the stability of sparfloxacin was observed with the cosolvents and surfactants investigated. The study suggests that cosolvents or surfactants at non-toxic concentrations could be incorporated into liquid pharmaceutical dosage forms of sparfloxacin to stabilize the preparations under acidic conditions.